BioCentury | Dec 19, 2018
Distillery Therapeutics

Inflammation; pulmonary

...published online Dec. 12, 2018 doi:10.1038/s41467-018-07698-6 CONTACT: Elisa Ciraolo, University of Turin, Turin, Italy email: Elisa.Ciraolo@mdc-berlin.de Claire...
BioCentury | Dec 4, 2018
Distillery Therapeutics

Neurology

...doi:10.1016/j.chembiol.2018.10.013 CONTACT: Erich E. Wanker, Max Delbrück Center for Molecular Medicine Berlin-Buch, Berlin, Germany email: ewanker@mdc-berlin.de Claire...
BioCentury | Nov 15, 2018
Translation in Brief

The bystander effect of Treg depletion

...by blocking the chemokine receptor’s interaction with its ligands chemokine CC motif ligand 22 (CCL22; MDC...
BioCentury | Oct 31, 2017
Distillery Techniques

Biomarkers

...2017 doi:10.1038/s41467-017-01220-0 CONTACT: Young-Ae Lee, Max Delbrück Center for Molecular Medicine Berlin-Buch, Berlin, Germany email: yolee@mdc-berlin.de Elizabeth...
BioCentury | Aug 10, 2017
Emerging Company Profile

Flexing against suppression

...to selectively inhibit Tregs.” FLX Bio’s compound blocks the chemokine receptor’s interaction with its ligands CCL22...
...in combination with checkpoint inhibitors to treat solid tumors, and is investigating biomarker candidates, including CCL22...
...Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Targets CCL17 - Chemokine CC motif ligand 17 CCL22 (MDC...
BioCentury | Jul 31, 2017
Distillery Techniques

Chemistry

...compound decreased levels of the inflammatory marker chemokine CC motif ligand 22 ( CCL22 ; MDC...
BioCentury | Jul 10, 2017
Distillery Therapeutics

Endocrine / Metabolic

...19, 2017 doi:10.1038/nn.4590 CONTACT: Matthew Poy, Max Delbrück Center for Molecular Medicine, Berlin, Germany email: matthew.poy@mdc-berlin.de Winnie...
BioCentury | Jan 11, 2017
Distillery Therapeutics

Neurology

...Molecular Medicine, Berlin, Germany email: k.poole@unsw.edu.au CONTACT: Gary R. Lewin, same affiliation as above email: glewin@mdc-berlin.de Hongjiang...
BioCentury | Oct 20, 2016
Distillery Therapeutics

Cancer

...chemokine CCL22 could help treat metastatic melanoma. In samples of patient skin metastases, levels of CCL22...
...in healthy volunteer skin samples, and in patient blood samples, numbers of Tregs expressing the CCL22...
...xenograft mouse models of metastatic melanoma. TARGET/MARKER/PATHWAY: Chemokine CC motif ligand 22 ( CCL22 , MDC...
BioCentury | Sep 26, 2016
Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

...The Max Delbrueck Center ( MDC ) granted Wilex’s Heidelberg Pharma GmbH subsidiary an option to...
...start in 2018 to treat multiple myeloma (MM). Wilex declined to disclose financial terms, and MDC...
Items per page:
1 - 10 of 48